Publication date: Jun 23, 2025
Chronic kidney disease represents an immunocompromising condition and a cause of a lower vaccine efficacy, even in patients undergoing maintenance dialysis. Recent SARS-CoV-2 outbreaks have prompted clinicians to better understand the underlying mechanisms and establish more suitable vaccination schedules. In a single-center, retrospective, observational study of patients undergoing maintenance dialysis in France, we studied the factors associated with the intensity of the humoral response to a SARS-CoV-2 vaccine in this population, including specific dialysis-related variables. After having received three doses of SARS-CoV-2 mRNA vaccine, a cohort of 80 patients was divided into low-responders (28 patients with an anti-SARS-CoV-2 antibody level of 50-1830 AU/mL) and responders (52 patients with an antibody level > 1830 AU/mL). We found that chronic heart failure (p
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | heart failure |
| disease | MESH | hypoalbuminemia |
| disease | MESH | Chronic kidney disease |
| drug | DRUGBANK | Tropicamide |
| pathway | REACTOME | Reproduction |
| disease | MESH | COVID-19 |